60753-14-2

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-Pyridyl)-1-butanol is used as a building block for the synthesis of drug candidates, leveraging its chiral nature to create enantiomerically pure compounds, which is crucial for the development of effective and safe medications.
Used in Fragrance Industry:
P4B is used as a component in the creation of fragrances, capitalizing on its pleasant floral odor to enhance the scent profiles of various products.
Used in Asymmetric Synthesis:
4-(3-Pyridyl)-1-butanol is employed as a chiral auxiliary in asymmetric synthesis, facilitating the production of enantiomerically enriched compounds, which is vital for the synthesis of biologically active molecules.
Used in Anti-Inflammatory Applications:
P4B has been studied for its potential as an anti-inflammatory agent, suggesting its use in the development of treatments for inflammatory conditions.
Used in Cancer Research:
4-(3-Pyridyl)-1-butanol is investigated for its potential as an inhibitor of enzymes involved in cancer cell proliferation, indicating its use in the development of novel anticancer therapeutics.

Upstream product

• 138487-20-4 4-(pyridin-3-yl)-1-but-3-ynol 
• 626-55-1 3-Bromopyridine 
• 174523-91-2 4-(3-pyridyl)butyl tert-butyldimethylsilyl ether 
• 60753-13-1 ethyl 4-(pyridin-3-yl)butanoate 
• 1120-90-7 3-iodopyridine 
• 500-22-1 3-pyridinecarboxaldehyde 
• 27678-09-7 4-pyridin-3-yl-butyronitrile 
• 21011-66-5 3-(3-chloropropyl)pyridine 
• 535972-85-1 4-(3-pyridyl)but-3-en-1-ol 

Downstream Products

• 97607-58-4 4-(3-pyridyl)butyl phenylpropynoate 
• 145912-93-2 4-(3-pyridinyl)butyraldehyde 
• 189754-09-4 N-Boc-pipecolic acid 1-phenyl-7-(3'-pyridyl)heptan-4-ol ester 
• 145912-94-3 1-phenyl-7-(3-pyridyl)heptan-4-ol 
• 189754-10-7 pipecolic acid 1-phenyl-7-(3'-pyridyl)heptan-4-ol ester 
• 174523-36-5 3-[4-[4-(5-trifluoromethyl-1,2,4-oxadiazol-3-yl)-2,6-dimethylphenoxy]-butyl]-pyridine 
• 97607-66-4 2,4,6-Trimethyl-benzenesulfonate1-amino-3-[4-(3-phenyl-propynoyloxy)-butyl]-pyridinium; 
• 97607-70-0 1-Ethoxycarbonylmethyl-3-[4-(3-phenyl-propynoyloxy)-butyl]-pyridinium; bromide 
• 192643-89-3 [2-[5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-2-(3,5-dimethylphenyl)-1H-indol-3-yl]ethyl]-[4-(pyridin-3yl)butyl]carbamic acid benzyl ester 

Relevant academic research and scientific papers

Synthesis and antitumor activity of novel pyridinium fullerene derivatives

Purpose: We have previously reported that some cationic fullerene derivatives exhibited anticancer activity, and they are expected to be a potential lead compound for an anti-drug resistant cancer agent. However, they are bis-adducts and a mixture of multiple regioisomers, which cannot be readily separated due to the variability of substituent positions on the fullerene cage. To overcome this issue, we evaluated the antiproliferative activities of a set of mono-adduct derivatives and examined their structure-activity relationship. In addition, the in vivo antitumor activity of selected derivatives was also examined. Methods: Nineteen pyridinium fullerene derivatives were newly designed and synthesized in this study. Their antiproliferative activities were evaluated using several cancer cell lines including drug-resistant cells. Furthermore, in vivo antitumor activity of several derivatives was investigated in mouse xenograft model of human lung cancer. Results: The derivatives inhibited the proliferation of cancer cell lines, including cisplatin-resistant cells and doxorubicin-resistant cells. It was also shown that compound 10 (10 μM), 13 (10 μM) and cis-14 (10 μM) induced the intracellular oxidative stress. In addition, compound 13 (20 mg/kg) and cis-14 (15 mg/kg) significantly exhibited antitumor activity in mouse xenograft model of human lung cancer. Conclusion: We synthesized a novel set of mono-adduct fullerene derivatives functionalized with pyridinium groups and found that most of them show potent antiproliferative activities against cancer cell lines and some of them show significant antitumor activities in vivo. We propose that these fullerene derivatives serve as the lead compounds for a novel type of antitumor agents.

Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimer’s Agents Based on Rational Design

Glutaminyl cyclase (QC) has been implicated in the formation of toxic amyloid plaques by generating the N-terminal pyroglutamate of β-amyloid peptides (pGlu-Aβ) and thus may participate in the pathogenesis of Alzheimer’s disease (AD). We designed a library of glutamyl cyclase (QC) inhibitors based on the proposed binding mode of the preferred substrate, Aβ3E?42. An in vitro structure-activity relationship study identified several excellent QC inhibitors demonstrating 5- to 40-fold increases in potency compared to a known QC inhibitor. When tested in mouse models of AD, compound 212 significantly reduced the brain concentrations of pyroform Aβ and total Aβ and restored cognitive functions. This potent Aβ-lowering effect was achieved by incorporating an additional binding region into our previously established pharmacophoric model, resulting in strong interactions with the carboxylate group of Glu327 in the QC binding site. Our study offers useful insights in designing novel QC inhibitors as a potential treatment option for AD.

CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS

Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.

2-Aryl-2,2-difluoroacetamide FKBP12 Ligands: Synthesis and X-ray Structural Studies

2-Aryl-2,2-difluoroacetamido-proline and pipecolate esters are high affinity FKBP12 ligands whose rotamase inhibitory activity is comparable to that seen for the corresponding ketoamides. X-ray structural studies suggest that the fluorine atoms participat

Heterocyclic derivatives of 2-(3,5-dimethylphenyl)tryptamine as GnRH receptor antagonists

A series of heterocyclic 2-(3,5-dimethylphenyl)tryptamine derivatives was prepared and evaluated on a rat gonadotropin releasing hormone receptor assay. The carbon tether length and heterocyclic ring attached to the amino group of 2-(3,5-dimethylphenyl)tr

Therapeutic phenoxyalkylheterocycles

Compounds of the formula STR1 wherein Q is chosen from the group consisting of pyridyl, pyrazyl, pyrimidyl, quinolyl, indolyl and 7-azaindolyl or any of these substituted with one or two substituents; Y is an alkylene bridge of 3-9 carbon atoms; R1 and R2 are each independently chosen from hydrogen, halo, alkyl, alkenyl, amino, alkylthio, hydroxy, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, alkoxy, nitro, carboxy, alkoxycarbonyl, dialkylaminoalkyl, alkylaminoalkyl, aminoalkyl, difluoromethyl, trifluoromethyl or cyano; R3 is alkoxycarbonyl, alkyltetrazolyl, substituted or unsubstituted phenyl or heterocyclyl, the N-oxide thereof, or a pharmaceutically acceptable acid addition salt thereof is an effective antipicornaviral agent.

New BHT ether compounds and their use as hypolipidemic and antiatherosclerotic drugs

Pharmaceutically-active BHT-omega pyridyl ethers of the formula selected from BHT-omega-pyridyl ether compounds of the formula: STR1 wherein m=1,3 for m=1, Σ=6-9 for m=3, Σ=5-11 Sum (Σ)=[m+n+1 (for oxygen)] wherein the bond between the two carbon atoms of the (CH2)n moiety most closely adjacent the pyridine ring is a single, double, or triple bond, and pharmaceutically-acceptable acid addition salts thereof, pharmaceutical compositions thereof, and a method of combating lipidemia and atherosclerosis therewith, are disclosed.

Synthesis of Peri-fused Indolizines and Azaindolizines by Intramolecular 1,3-Dipolar Cycloaddition of 3-(Phenylpropynoyloxyalkyl)pyridine N-Ylides

Treatment of 3-(phenylpropynoyloxymethyl)-N-aminopyridium salt with potassium carbonate in methanol gave unexpectedly 4-methyl-2-phenylpyrazolopyridine and methyl 6- and 4-hydroxymethyl-2-phenylpyrazolopyridine-3-carboxylates.Similar treatme

Structural Factors Affecting the Basicity of ω-Pyridylalkanols, ω-Pyridylalkanamides and ω-Pyridylalkylamines

The present paper describes the preparation by conventional methods (when not available commercially) and the pKa-determination of the α-, β- and γ-isomers of pyridylethanamide, 3-pyridylpropanamide, 4-pyridylbutanamide, 5-pyridylpentanamide, pyridylmethanol, 2-pyridylethanol, 3-pyridylpropanol, 4-pyridylbutanol, 5-pyridylpentanol, pyridylmethylamine, 2-pyridylethylamine, 3-pyridylpropylamine, 4-pyridylbutylamine, and 5-pyridylpentylamine.While a field effect accounts for many variations in pKa as a function of chain length, marked inductive effects are operative in some methyl and ethyl homologs.The pKa-decreasing influence of an intramolecular H-bond is also apparent in some lower homologs belonging to the α-series.